Charles River Laboratories International (CRL) Operating Leases (2019 - 2026)

Charles River Laboratories International has reported Operating Leases for 8 years, with the latest figure at $407.7 million in Q2 2026.

• On a quarterly basis, Operating Leases fell 10.13% year-over-year to $407.7 million in Q2 2026; TTM through Jun 2026 was $407.7 million, a 10.13% decrease from a year earlier, with the FY2025 full-year figure at $434.0 million, down 19.31% from the prior year.
• Operating Leases was $407.7 million for Q2 2026 at Charles River Laboratories International, up from $393.1 million in the prior quarter.
• The five-year high for Operating Leases was $537.9 million in Q4 2024, with the low at $264.4 million in Q1 2022.
• Average Operating Leases over 5 years is $419.1 million, with a median of $423.4 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2025: Operating Leases jumped 58.2% in 2023, then dropped 19.31% in 2025.
• Over 5 years, Operating Leases stood at $436.3 million in 2022, then grew by 8.68% to $474.1 million in 2023, then grew by 13.46% to $537.9 million in 2024, then fell by 19.31% to $434.0 million in 2025, then declined by 6.07% to $407.7 million in 2026.
• The last three Operating Leases figures came in at $407.7 million (Q2 2026), $393.1 million (Q1 2026), and $434.0 million (Q4 2025), per Business Quant data.